Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, … Read more
Mineralys Therapeutics, Inc. Common Stock (MLYS) - Net Assets
Latest net assets as of September 2025: $576.43 Million USD
Based on the latest financial reports, Mineralys Therapeutics, Inc. Common Stock (MLYS) has net assets worth $576.43 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($599.95 Million) and total liabilities ($23.52 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $576.43 Million |
| % of Total Assets | 96.08% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Mineralys Therapeutics, Inc. Common Stock - Net Assets Trend (2020–2024)
This chart illustrates how Mineralys Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mineralys Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual net assets of Mineralys Therapeutics, Inc. Common Stock from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $191.26 Million | -20.69% |
| 2023-12-31 | $241.15 Million | +561.37% |
| 2022-12-31 | $-52.27 Million | -128.00% |
| 2021-12-31 | $-22.93 Million | -537.34% |
| 2020-12-31 | $-3.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mineralys Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 29891500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Components | $493.77 Million | 258.17% |
| Total Equity | $191.26 Million | 100.00% |
Mineralys Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Mineralys Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Central Retail Corporation Public Company Limited
BK:CRC
|
$1.43 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
$1.43 Billion |
|
Russel Metals Inc
PINK:RUSMF
|
$1.43 Billion |
|
TriCo Bancshares
NASDAQ:TCBK
|
$1.44 Billion |
|
Deliveroo Holdings PLC
PINK:DROOF
|
$1.43 Billion |
|
Visual China Group Co Ltd
SHE:000681
|
$1.43 Billion |
|
Innovative Industrial Properties Inc
NYSE:IIPR
|
$1.43 Billion |
|
Ube Industries Ltd
PINK:UBEOF
|
$1.43 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mineralys Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 241,154,000 to 191,257,000, a change of -49,897,000 (-20.7%).
- Net loss of 177,810,000 reduced equity.
- Share repurchases of 221,000 reduced equity.
- New share issuances of 116,059,000 increased equity.
- Other comprehensive income increased equity by 251,636,000.
- Other factors decreased equity by 239,561,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-177.81 Million | -92.97% |
| Share Repurchases | $221.00K | -0.12% |
| Share Issuances | $116.06 Million | +60.68% |
| Other Comprehensive Income | $251.64 Million | +131.57% |
| Other Changes | $-239.56 Million | -125.26% |
| Total Change | $- | -20.69% |
Book Value vs Market Value Analysis
This analysis compares Mineralys Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.35x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-0.78 | $25.02 | x |
| 2021-12-31 | $-4.60 | $25.02 | x |
| 2022-12-31 | $-10.12 | $25.02 | x |
| 2023-12-31 | $6.66 | $25.02 | x |
| 2024-12-31 | $3.94 | $25.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mineralys Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -92.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.08x
- Recent ROE (-92.97%) is below the historical average (-24.56%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.07 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.12 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-24.57 Million |
| 2023 | -29.81% | 0.00% | 0.00x | 1.04x | $-96.01 Million |
| 2024 | -92.97% | 0.00% | 0.00x | 1.08x | $-196.94 Million |
Industry Comparison
This section compares Mineralys Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mineralys Therapeutics, Inc. Common Stock (MLYS) | $576.43 Million | 0.00% | 0.04x | $1.43 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |